Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital

Hamoud A¹, Almeida G¹, Kurumthottical M², Goodluck A³, Yang E³, Pasu R⁴, Quijano C³ and Younis S³

¹Department of Ophthalmology Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust UK, United Kingdom

²Ophthalmology Department, Queen Elizabeth Hospital Birmingham UK, United Kingdom

³Medical Retina Department, Western Eye Hospital- Imperial College Healthcare NHS Trust UK, United Kingdom

⁴Moorfields Eye Hospital NHS Foundation Trust UK, United Kingdom

*Corresponding Author : Hamoud Aseel
FRCS Glasg, Department of Ophthalmology Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust UK, United Kingdom
Tel: 447470185991
E-mail: aseelhamoud@yahoo.com

Received: February 01, 2018 Accepted: March 14, 2018 Published: March 21, 2018

Citation: Hamoud A, Almeida G, Kurumthottical M, Goodluck A, Yang E, et al. (2018) Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital. Int J Ophthalmic Pathol 7:1.doi: 10.4172/2324-8599.1000215

Wet age-related macular degeneration wARMD is the leading cause of central visual loss in elderly patients in the developed countries. Overexpression of vascular endothelial grown factor (VEGF) is known to play a major role in the pathogenesis of choroidal neovascularization. Aflibercept is a fully human, recombinant fusion protein that inhibits VEGF. It has a higher tendency to combine with VEGF-A and it blocks other factors such as VEGF-B and placental growth.